Combined HA and PLLA Formulation
RePLLAy HA + PLLA Biostimulatory Filler
Facial volume · Collagen biostimulation
RePLLAy combines cross-linked hyaluronic acid with poly-L-lactic acid microspheres in a pre-filled formulation for professional aesthetic medicine. It is supplied as two 1 ml pre-filled syringes. Request the current technical documentation to assess the product for your market.
CE-marked product. Contact RAMCODE for regulatory documentation.
HA Component
Cross-linked HA
PLLA Content
18% microspheres
Microsphere Size
20–50 µm
Indicative Duration
Up to 24 months
Clinical Application
Treatment Areas
About
RePLLAy Product Overview
RePLLAy combines cross-linked sodium hyaluronate with poly-L-lactic acid (PLLA) microspheres. The supplied catalogue describes 18% PLLA microspheres in a pre-filled formulation, with two 1 ml syringes per pack.
This combined HA and PLLA composition distinguishes RePLLAy from the HA-only products in the range. Request the current instructions for use and supporting technical and clinical documentation to assess its intended use and the information applicable to your market.
Compare Volume Plus HA filler and Stimulate micro cross-linked HA, or discuss RePLLAy distribution with RAMCODE.
Technical Data
Product Specifications
Specifications are summarised from the supplied product catalogue. Indicative durations are not guaranteed outcomes. Consult the current instructions for use and supporting technical documentation for your territory.
Cross-linked HA + 18% PLLA microspheres | 20–50 µm | 2 × 1 ml
HA Component
Cross-linked HA
PLLA Content
18% microspheres
Microsphere Size
20–50 µm
Indicative Duration
Up to 24 months
Volume
2 × 1ml
Formulation
HA + PLLA
Packaging
2 syringes × 1ml pre-filled
Formulation Overview
Understanding the HA and PLLA Combination
01
HA Component
HA gel
RePLLAy contains cross-linked sodium hyaluronate as part of its combined formulation. Review the current documentation for the product’s specifications and intended use.
02
PLLA Component
PLLA 18%
The supplied catalogue describes PLLA microspheres dispersed in the HA formulation. Product-specific technical and clinical information should be consulted when assessing performance.
03
Professional Assessment
By request
Request current evidence, instructions for use and information relevant to your territory. This overview is not a treatment timeline or a guarantee of clinical results.
Formulation Information
Combined HA and PLLA Formulation
RePLLAy combines an HA gel with PLLA microspheres. The catalogue lists an 18% PLLA content and a microsphere size range of 20–50 µm. These composition details do not, on their own, establish release kinetics or guarantee a particular clinical response.
Explore the HA and PLLA formulation overview or request current product-specific evidence.
Conceptual animation — not microscopy or clinical evidence.